India’s pharmaceutical regulatory system is confronting a challenge that scarcely existed when the Drugs Rules were framed in 1945. Medicines requiring medical supervision can now be promoted to millions of consumers through smartphones, online pharmacies, social-media influencers and digital advertising networks.
A prescription medicine may reach potential buyers through a sponsored video, an online discount or a seemingly innocuous health-awareness campaign, often without adequate information about its risks. The government is now seeking to close a regulatory gap that has become increasingly significant with the rapid expansion of digital healthcare services.
The Union Ministry of Health and Family Welfare has proposed amendments to the Drugs Rules, 1945, to extend restrictions on advertising prescription medicines to retailers, wholesalers and distributors.
The draft amendment, notified through Gazette Notification G.S.R. 861(E), dated September 28, 2026, seeks to prohibit holders of drug sale and distribution licences from advertising medicines classified under Schedules H, H1 and X without prior sanction from the Central Government. The proposal reflects growing concern that pharmaceutical advertising restrictions must apply throughout the supply chain rather than primarily to manufacturers.
The Ministry announced the initiative on October 9, describing it as an effort to strengthen pharmaceutical oversight and reduce the risks associated with inappropriate self-medication. The proposal follows recommendations made during the 93rd meeting of the Drugs Technical Advisory Board on February 16, 2026.
It represents an important regulatory intervention at a time when pharmaceutical commerce is increasingly influenced by digital marketing, consumer-facing healthcare applications and promotional content that can reach patients without passing through conventional medical channels.
Closing the regulatory gap
Under the existing regulatory framework, pharmaceutical manufacturers are subject to restrictions on advertising medicines covered by Schedules H, H1 and X. However, equivalent provisions have not explicitly applied to businesses licensed to sell, stock or distribute these medicines. This distinction has become increasingly consequential as pharmaceutical distribution has moved beyond conventional retail pharmacies.
The proposed amendment would insert sub-rule (22) into Rule 65 of the Drugs Rules, bringing retail and wholesale licence-holders within the advertising restrictions and extending regulatory accountability across additional participants in the pharmaceutical supply chain.
The public-health implications are considerable. Schedule H includes numerous prescription-only medicines, while Schedule H1 imposes additional controls on specified medicines, including certain antibiotics. Schedule X covers medicines subject to particularly stringent controls because of their potential for misuse or dependence.
Unsupervised antibiotic consumption contributes to antimicrobial resistance, while inappropriate use of psychotropic medicines can cause dependence, adverse reactions and serious medical complications. The proposed restrictions therefore address more than misleading commercial practices; they seek to reinforce the principle that medicines requiring professional supervision should not be marketed like ordinary consumer products.
The challenge of enforcing digital advertising restrictions
The most difficult question concerns enforcement in an increasingly decentralised advertising ecosystem. Traditional pharmaceutical advertising generally involves identifiable manufacturers, distributors and publishers. Digital promotion can involve multiple intermediaries, including e-pharmacies, marketing agencies, social-media platforms, content creators and affiliate advertisers.
A promotional campaign might originate with a licensed pharmacy, be designed by an advertising agency and reach consumers through an influencer operating on an international platform. Identifying the responsible parties and establishing liability in such circumstances will require regulatory clarity and coordination across institutions.
The proposed amendment establishes obligations for drug licence-holders, but it does not itself create a comprehensive liability framework covering every digital intermediary. A social-media platform hosting an advertisement is not necessarily subject to the same licensing conditions as the pharmacy commissioning it.
Regulators will therefore need to determine how existing pharmaceutical laws and digital-platform obligations interact when prohibited advertisements appear online. Questions concerning sponsored content, affiliate marketing, promotional links, algorithmically distributed advertisements and advertisements originating outside India could become particularly important during implementation.
The growing popularity of prescription weight-loss medicines illustrates the urgency of stronger oversight. Medicines based on GLP-1 receptor agonists have attracted considerable public attention, creating opportunities for inappropriate promotion through celebrity endorsements, influencer campaigns and indirect advertising.
In March 2026, the Central Drugs Standard Control Organisation issued an advisory addressing surrogate advertising of prescription-only medicines, including GLP-1-based treatments. The regulator warned against promotional practices disguised as disease-awareness initiatives, influencer engagement or corporate campaigns intended to generate commercial visibility for prescription products.
These developments demonstrate that the government faces two interconnected challenges: extending legal restrictions across the pharmaceutical supply chain and identifying promotional activity that deliberately avoids conventional advertising formats. An influencer discussing a medicine without directly recommending its purchase may still be participating in a commercial campaign.
Similarly, a disease-awareness advertisement may become a vehicle for promoting a particular prescription product. Effective enforcement will depend on regulators’ ability to distinguish independent health communication from paid promotional activity, including through examination of commercial relationships, advertising disclosures and digital evidence.
Central and state regulators must work together
India’s federal drug-regulatory architecture presents another implementation challenge. CDSCO performs central regulatory functions, while state drug-control authorities exercise important licensing and enforcement responsibilities. A pharmacy licensed in one state could commission promotional content accessible throughout the country, creating jurisdictional complications when violations are detected elsewhere.
Regulators will need mechanisms for identifying prohibited advertisements, preserving digital evidence, sharing information and initiating action against responsible licence-holders. Consistent enforcement standards will be essential to prevent regulatory arbitrage between jurisdictions.
The Drugs Consultative Committee, at its April 2026 meeting, recommended that state and Union Territory drug controllers maintain vigilance against misleading promotion of prescription medicines and take appropriate enforcement action while informing CDSCO. A coordinated national reporting mechanism could strengthen these efforts by enabling state authorities to flag suspicious advertisements and share information about repeat offenders.
Technology-enabled monitoring could also help identify advertisements involving restricted medicines, although automated systems would require human verification to distinguish unlawful promotion from legitimate medical information.
Another important challenge involves distinguishing prohibited advertising from genuine patient education. Consumers increasingly depend on digital platforms to understand diseases, treatment options, medicine availability and potential side effects. A pharmacy providing factual information about a prescription medicine performs a different function from one encouraging consumers to purchase that medicine through promotional claims.
The distinction becomes complicated when educational material contains product references, commercial links or purchasing incentives. Clear regulatory guidance will be necessary to ensure that restrictions on advertising do not inadvertently obstruct access to reliable healthcare information.
The consultation and the road ahead
The proposed prior-approval requirement also raises practical questions about administrative capacity and regulatory transparency. Authorities will need clear procedures for evaluating applications, defining permissible communications and determining whether particular advertisements require approval.
Without transparent criteria and reasonable processing timelines, legitimate pharmaceutical communication could face uncertainty while sophisticated advertisers continue exploiting regulatory ambiguities. The Ministry has invited objections and suggestions within a 30-day consultation window, giving pharmacists, pharmaceutical manufacturers, digital platforms, medical professionals and consumer organisations an opportunity to recommend improvements before the rules are finalised.
Ultimately, the proposed amendment represents an important extension of pharmaceutical regulation into India’s rapidly changing digital marketplace. Its effectiveness will depend not merely on prohibiting unauthorised advertisements, but on creating an enforcement system capable of identifying violations, allocating responsibility and taking consistent action across jurisdictions.
As digital healthcare expands, the government must balance commercial innovation and access to information with the fundamental obligation to protect patients from unsafe medication practices. The larger challenge is to ensure that the speed and reach of pharmaceutical promotion do not exceed the safeguards necessary for public health.
